Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sabina Chiaretti

Sabina Chiaretti

MD, PhD
Sapienza University of Rome
Retrospective real-world study evaluating compassionate use of ponatinib in R/R Ph-like ALL 1:17
Retrospective real-world study evaluating compassionate use of ponatinib in R/R Ph-like ALL
Sabina Chiaretti • 10 Dec 2023
The feasibility of TKI treatment discontinuation in patients with Ph+ ALL 1:32
The feasibility of TKI treatment discontinuation in patients with Ph+ ALL
Sabina Chiaretti • 10 Dec 2023
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL 1:05
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL
Sabina Chiaretti • 10 Dec 2023
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL 1:59
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL
Sabina Chiaretti • 10 Dec 2023
Final results of the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph- B-ALL 1:54
Final results of the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph- B-ALL
Sabina Chiaretti • 10 Dec 2023
The impact of age on the prognosis of patients with ALL 1:25
The impact of age on the prognosis of patients with ALL
Sabina Chiaretti • 11 Dec 2022
Major unmet needs in Ph+ ALL and future outlooks 1:00
Major unmet needs in Ph+ ALL and future outlooks
Sabina Chiaretti • 11 Dec 2022
An update on the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph-like ALL 1:39
An update on the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph-like ALL
Sabina Chiaretti • 11 Dec 2022
Venetoclax and navitoclax combination therapy for R/R ALL or lymphoblastic lymphoma 1:23
Venetoclax and navitoclax combination therapy for R/R ALL or lymphoblastic lymphoma
Sabina Chiaretti • 11 Dec 2022
Campus ALL updates: the safety and efficacy of daratumumab for the treatment of ALL 1:28
Campus ALL updates: the safety and efficacy of daratumumab for the treatment of ALL
Sabina Chiaretti • 12 Jun 2022
An update on the GIMEMA LAL2116 trial 1:40
An update on the GIMEMA LAL2116 trial
Sabina Chiaretti • 12 Jun 2022
Managing ALL patients who relapse after transplantation 1:14
Managing ALL patients who relapse after transplantation
Sabina Chiaretti • 12 Jun 2022
GIMEMA LAL2116 trial and the GIMEMA LAL1509 protocol 10:09
GIMEMA LAL2116 trial and the GIMEMA LAL1509 protocol
Sabina Chiaretti • 24 Jun 2021
Patient selection for BiTEs therapies 2:35
Patient selection for BiTEs therapies
Sabina Chiaretti • 24 Jun 2021
Neuf: real-world data on blinatumomab for ALL 1:35
Neuf: real-world data on blinatumomab for ALL
Sabina Chiaretti • 9 Dec 2019
Gimema D-Alba: chemo-free Ph+ ALL treatment 5:27
Gimema D-Alba: chemo-free Ph+ ALL treatment
Sabina Chiaretti
The content of VJHemOnc is intended for healthcare professionals